These functions included the ability to sensitize in vivo against both MHC class I and MHC class II-restricted peptides and the ability to generate therapeutically-meaningful immune responses in a mouse model of HER2pos breast cancer using a known rat ErbB2/HER2 CTL epitope peptide. This evidence concerns the gene ERBB2 and breast cancer.